FTC Counters POM Appeal Of False Advertising Decision
This article was originally published in The Tan Sheet
Executive Summary
FTC rebuts POM Wonderful’s attempt to paint the agency as overly aggressive and demanding in concluding that the firm knowingly mislead consumers with disease prevention claims for its pomegranate juice and supplements. The agency responds to POM’s appeal of a January 2013 order against the firm.
You may also be interested in...
POM Wonderful Asks Court To Vacate “Draconian” FTC Order
The nearly three-year battle between FTC and POM Wonderful moves to a federal appeals court, where the pomegranate juice and supplement firm asks the judges to nix the commission’s order that POM conduct two randomized controlled trials to support disease-related health claims.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.